พญ. เกศรินทร์ ถานะภิรมย์ ได้ไปร่วมงานประชุมวิชาการ EASL The Home of Hepatology 2016 ณ ประเทศสเปน ระหว่างวันที่ 13-17 เมษายน 2559 และยังได้เสนอผลงานวิจัยในหัวข้อ PREVALENCE OF HEPATITIS E VIRUS IN SOLID ORGAN TRANSPLANT RECIPIENTS: A META-ANALYSIS
PREVALENCE OF HEPATITIS E VIRUS IN SOLID ORGAN TRANSPLANT RECIPIENTS: A META-ANALYSIS
Kessarin Thanapirom*1, Paweena Susantitaphong2, Sombat Treeprasertsuk1, Kearkiat Praditpornsilpa2, Piyawat Komolmit1
1Medicine, GASTROENTEROLOGY UNIT, DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, CHULALONGKORN UNIVERSITY, 2Medicine, DIVISION OF NEPHROLOGY, DEPARTMENT OF MEDICINE, FACULTY OF MEDICINE, CHULALONGKORN UNIVERSITY, Bangkok, Thailand
Background and Aims: Hepatitis E virus (HEV) infection usually causes acute but spontaneous recovery hepatitis in immunocompetent individuals. Recently, persistent HEV infection has been described among immunosuppressed patients following solid organ transplantation (SOT). Prevalence of HEV seropositivity in SOT recipients varies in different world regions. Our study aim to systemically examine the HEV seroprevalence in this patients population.
Methods: A systematic review (March 1, 2015) of large cohort studies was conducted to estimate the prevalence of HEV infection in SOT recipients. Chronic HEV infection was defined by the presence of HEV RNA for at least 3 months in blood sample. Random effects model meta-analyses were used to generate summary estimates.
Results: There were 19 studies identified (n= 5,296 patients). Most studies originated from Europe (n=15 studies). The rest were from America (n=3 studies), and Asia (n=1 study). By meta-analysis, the pooled anti-HEV-IgG seroprevalence was 10.8% (95% CI, 7.4-15.5%) in 14 included studies (n=2,419 patients). More prevalence rates were observed in America and Asia when compared with European countries 20.1% (95% CI, 10.3-35.4%) and 25.4% (95% CI, 19.9-31.8%) vs 8.5% (95% CI, 5.3-13.3%), respectively. The pooled prevalence rate of HEV-RNA in 16 included studies (n = 5,043 patients) was 2.4% (95% CI, (1.5-3.8%). In addition, the pooled prevalence of chronic HEV infection was 1.6% (95%CI, 1.1-2.3%) in 14 included studies (n = 4,719 patients). Most of patients with chronic infection in these studies were infected with HEV genotype 3.
Conclusions: In SOT recipients, Anti-HEV IgG could be detected during acute or chronic phase of infection, and also in previous HEV exposure. The seroprevalence varied among the regions, rather low in Europe. Detection of HEV RNA in blood ascertained the diagnosis of active infection. SOT recipients had a risk for chronic HEV infection, but the prevalence was low.
Disclosure of Interest: None Declared